TISLELIZUMAB-JSGR

TISLELIZUMAB-JSGR was reported 224 times

TISLELIZUMAB-JSGR is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 OESOPHAGEAL WALL HYPERTROPHY 1 0.0294
1 PULMONARY TUMOUR THROMBOTIC MICROANGIOPATHY 1 0.0130
2 TUMOUR PERFORATION 4 0.0126
3 VASCULITIS GASTROINTESTINAL 1 0.0091
4 TRACHEAL FISTULA 1 0.0065
5 MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME 1 0.0044
6 METASTASES TO CHEST WALL 1 0.0029
7 CYTOMEGALOVIRUS ENTERITIS 1 0.0028
8 PORTAL VENOUS GAS 1 0.0028
9 MOUTH BREATHING 1 0.0023
10 GASTROINTESTINAL STENOSIS 1 0.0022
11 IMMUNE-MEDIATED THYROIDITIS 1 0.0020
12 IMMUNE-MEDIATED ENCEPHALITIS 1 0.0019
13 TUMOUR RUPTURE 1 0.0018
14 MEDIASTINITIS 1 0.0017
15 MEDICAL DEVICE SITE INFECTION 1 0.0016
16 PERFORATION 1 0.0012
17 OESOPHAGEAL PERFORATION 1 0.0012
18 ENZYME LEVEL INCREASED 1 0.0012
19 PROCALCITONIN INCREASED 1 0.0009
20 PERIPHERAL SENSORIMOTOR NEUROPATHY 1 0.0008
21 PULMONARY SEPSIS 1 0.0007
22 DISEASE PROGRESSION 80 0.0007
23 LYMPHADENOPATHY 19 0.0005
24 ADRENAL DISORDER 1 0.0005
25 ENTEROCOLITIS 3 0.0005
26 ATRIAL TACHYCARDIA 1 0.0005
27 LICHEN PLANUS 1 0.0004
28 PERFORMANCE STATUS DECREASED 2 0.0004
29 DIABETIC NEUROPATHY 2 0.0004
30 APPENDICITIS PERFORATED 1 0.0004
31 FEMORAL NECK FRACTURE 2 0.0004
32 TYPE IV HYPERSENSITIVITY REACTION 1 0.0004
33 DUODENAL ULCER HAEMORRHAGE 1 0.0003
34 METASTASES TO LYMPH NODES 2 0.0003
35 CAROTID ARTERY STENOSIS 1 0.0003
36 NEUTROPENIC SEPSIS 2 0.0003
37 IMMUNE-MEDIATED ENTEROCOLITIS 1 0.0003
38 METASTASES TO LUNG 3 0.0003
39 MALIGNANT NEOPLASM PROGRESSION 25 0.0002
40 LUNG NEOPLASM 1 0.0002
41 METASTASES TO LIVER 4 0.0002
42 ILEUS PARALYTIC 1 0.0002
43 CARDIAC TAMPONADE 1 0.0002
44 RASH VESICULAR 1 0.0002
45 HYPERVOLAEMIA 1 0.0002
46 HYPERAMMONAEMIA 1 0.0002
47 TOXIC ENCEPHALOPATHY 1 0.0002
48 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 2 0.0002
49 THROMBOCYTOPENIA 21 0.0002
50 NEUTROPHIL COUNT DECREASED 7 0.0002
51 HYPERTRIGLYCERIDAEMIA 1 0.0002
52 POLYNEUROPATHY 2 0.0002
53 C-REACTIVE PROTEIN INCREASED 6 0.0002
54 ADRENAL INSUFFICIENCY 2 0.0002
55 CHOLANGITIS 1 0.0002
56 METASTASES TO CENTRAL NERVOUS SYSTEM 2 0.0002
57 HEPATITIS ACUTE 1 0.0002
58 HYPONATRAEMIA 8 0.0001
59 PULMONARY TOXICITY 1 0.0001
60 MYELOSUPPRESSION 5 0.0001
61 HYPOTHYROIDISM 4 0.0001
62 ANAPHYLACTIC SHOCK 3 0.0001
63 IMMUNOSUPPRESSION 1 0.0001
64 ANAEMIA 21 0.0001
65 PNEUMOCYSTIS JIROVECII PNEUMONIA 1 0.0001
66 INFUSION RELATED REACTION 6 0.0001
67 STEVENS-JOHNSON SYNDROME 2 0.0001
68 HEPATOTOXICITY 2 0.0001
69 PERICARDIAL EFFUSION 2 0.0001
70 VASCULITIS 1 0.0001
71 INTERSTITIAL LUNG DISEASE 4 0.0001
72 CYTOPENIA 1 0.0001
73 HEPATIC FUNCTION ABNORMAL 3 0.0001
74 PNEUMONIA ASPIRATION 2 0.0001
75 HEPATITIS 2 0.0001
76 FEBRILE NEUTROPENIA 5 0.0001
77 RENAL IMPAIRMENT 6 0.0001
78 STOMATITIS 4 0.0001
79 TOXIC EPIDERMAL NECROLYSIS 1 0.0001
80 DEVICE RELATED INFECTION 1 0.0001
81 LYMPHOMA 1 0.0001
82 METASTASES TO BONE 1 0.0001
83 ASPARTATE AMINOTRANSFERASE INCREASED 3 0.0001
84 HYPERGLYCAEMIA 2 0.0001
85 NEUROPATHY PERIPHERAL 5 0.0001
86 CHOLESTASIS 1 0.0001
87 CYTOKINE RELEASE SYNDROME 1 0.0000
88 FEEDING DISORDER 1 0.0000
89 ALANINE AMINOTRANSFERASE INCREASED 3 0.0000
90 DERMATITIS 1 0.0000
91 ALTERED STATE OF CONSCIOUSNESS 1 0.0000
92 MELAENA 1 0.0000
93 SHOCK 1 0.0000
94 DECREASED APPETITE 10 0.0000
95 CEREBRAL INFARCTION 1 0.0000
96 LEUKOPENIA 2 0.0000
97 DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 1 0.0000
98 DEAFNESS 1 0.0000
99 BRADYCARDIA 2 0.0000
100 PNEUMONIA 12 0.0000
101 LIVER FUNCTION TEST ABNORMAL 1 0.0000
102 ASCITES 1 0.0000
103 OESOPHAGEAL CARCINOMA 1 0.0000
104 HEPATIC FAILURE 1 0.0000
105 THERAPEUTIC RESPONSE DECREASED 2 0.0000
106 GYNAECOMASTIA 1 0.0000
107 CYSTITIS 1 0.0000
108 HIP FRACTURE 1 0.0000
109 SKIN DISORDER 1 0.0000
110 OFF LABEL USE 26 0.0000
111 NEOPLASM PROGRESSION 1 0.0000
112 WHITE BLOOD CELL COUNT DECREASED 3 0.0000
113 RESPIRATORY FAILURE 2 0.0000
114 PYREXIA 9 0.0000
115 CARDIAC FAILURE 2 0.0000
116 CARDIAC ARREST 2 0.0000
117 WITHDRAWAL SYNDROME 1 0.0000
118 MENTAL DISORDER 1 0.0000
119 HYPOKALAEMIA 1 0.0000
120 INFECTION 3 0.0000
121 LUNG DISORDER 1 0.0000
122 PRODUCT USE IN UNAPPROVED INDICATION 5 0.0000
123 INFLAMMATION 1 0.0000
124 PANCREATITIS 1 0.0000
125 PLATELET COUNT DECREASED 2 0.0000
126 RASH PRURITIC 1 0.0000
127 HAEMATOCHEZIA 1 0.0000
128 ANAPHYLACTIC REACTION 1 0.0000
129 CHILLS 2 0.0000
130 SURGERY 1 0.0000
131 NEUTROPENIA 2 0.0000
132 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 1 0.0000
133 UNDERDOSE 1 0.0000
134 ACUTE KIDNEY INJURY 2 0.0000
135 TREATMENT FAILURE 1 0.0000
136 CARDIAC DISORDER 1 0.0000
137 DYSPHAGIA 1 0.0000
138 PULMONARY EMBOLISM 1 0.0000
139 DEATH 9 0.0000
140 ALOPECIA 2 0.0000
141 SYNCOPE 1 0.0000
142 MALAISE 4 0.0000
143 FALL 3 0.0000
144 SEPSIS 1 0.0000
145 SEIZURE 1 0.0000
146 GENERAL PHYSICAL HEALTH DETERIORATION 1 0.0000
147 LOSS OF CONSCIOUSNESS 1 0.0000
148 NAUSEA 6 0.0000
149 DEHYDRATION 1 0.0000
150 HYPOAESTHESIA 1 0.0000
151 VOMITING 3 0.0000
152 CEREBROVASCULAR ACCIDENT 1 0.0000
153 COVID-19 1 0.0000
154 CHEST PAIN 1 0.0000
155 HYPERSENSITIVITY 1 0.0000
156 ASTHENIA 2 0.0000
157 DIARRHOEA 3 0.0000
158 RASH 2 0.0000
159 WEIGHT DECREASED 1 0.0000
160 CONDITION AGGRAVATED 1 0.0000
161 HEADACHE 2 0.0000
162 PRURITUS 1 0.0000
163 DRUG INEFFECTIVE 3 0.0000
164 DIZZINESS 1 0.0000
165 DYSPNOEA 1 0.0000
166 PAIN 1 0.0000
167 FATIGUE 1 0.0000